Purple Biotech Ltd. (PPBT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
Why Is Purple Biotech Stock Trading Higher On Monday?
On Monday, Purple Biotech Ltd PPBT reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC).
What Makes Purple Biotech (PPBT) a New Buy Stock
Purple Biotech (PPBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Purple Biotech Ltd. (PPBT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Purple Biotech Ltd. ever had a stock split?
Purple Biotech Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Gil Efron CEO | NASDAQ (CM) Exchange | 74638P109 CUSIP |
| IL Country | 9 Employees | - Last Dividend | 2 Mar 2026 Last Split | 20 Nov 2015 IPO Date |
Overview
Purple Biotech Ltd. operates within a highly specialized sector of the biotech industry, focusing on the development of innovative cancer therapies designed to overcome two significant challenges in cancer treatment: tumor immune evasion and drug resistance. The company is engaged in clinical-stage research and development, aiming to introduce novel treatments that can significantly improve the outcomes for cancer patients, particularly in the United States. Initially known as Kitov Pharma Ltd, the company rebranded to Purple Biotech Ltd. in December 2020, signaling a new focus or phase in its operations. Situated in Rehovot, Israel, Purple Biotech demonstrates its commitment to advancing cancer treatment through its progress in clinical trials and strategic collaborations, such as the one with Bristol Myers Squibb Company.
Products and Services
Purple Biotech Ltd. is advancing a promising oncology pipeline, with each product at different stages of development, from preclinical investigations to Phase 2 clinical trials. These include:
- CM24: This humanized monoclonal antibody targets and blocks the interactions of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), and is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors. Currently, CM24 is in a Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma. The significance of CM24 lies in its innovative approach to enhance the body's immune response against cancer cells, offering a novel therapeutic option for a particularly aggressive cancer type.
- NT219: As a small molecule, NT219 specifically targets and inhibits insulin receptor substrate 1 and 2, as well as signal transducer and activator of transcription (STAT) proteins. By disrupting these pathways, NT219 could potentially halt the growth and spread of cancer cells. It is in Phase 1/2 clinical trials for treating recurrent and/or metastatic squamous cell carcinoma of the head and neck, as well as colorectal adenocarcinoma. NT219 represents a strategic focus on targeting the molecular aberrations that contribute to cancer proliferation and resistance to existing treatments.
- IM1240: Still in the preclinical stage, IM1240 is a multi-valent antibody engineered to activate the immune system's anti-tumoral response against tumors positive for the 5T4 antigen. This approach could provide a broad application against various cancers expressing this antigen, illustrating the company's ongoing efforts to diversify and strengthen its oncology pipeline.
Purple Biotech's collaboration with Bristol Myers Squibb to evaluate CM24 in combination with the PD-1 inhibitor nivolumab, alongside chemotherapy, underscores the company's strategy of exploring synergistic effects between different cancer therapies. This collaborative effort aims to expand the treatment possibilities and improve clinical outcomes for cancer patients, reflecting the dynamic and innovative nature of Purple Biotech's research and development activities.
